Literature DB >> 18359082

Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia.

Lijuan Chen1, Yaping Zhang, Wenjuan Zheng, Yujie Wu, Chun Qiao, Lei Fan, Wei Xu, Jianyong Li.   

Abstract

BACKGROUND AND OBJECTIVES: The incidence of chronic lymphocytic leukemia (CLL) in Asian countries is lower than that in the Western ones, where CLL is the most common leukemia. It is a clinically heterogeneous disease, with survival ranging from a few months to decades. The mutation status of the immunoglobulin variable heavy chain (IgVH) gene has significantly improved prediction of the risk for disease progression. We investigated the frequency and mutation status of IgVH gene expression in Chinese patients with CLL.
METHODS: IgVH gene segments usage and mutation status were investigated by multiplex RT-PCR, and the relationship between IgVH somatic mutation status and the expression of CD38 and ZAP-70 was analyzed in 65 CLL patients.
RESULTS: Forty-five (69.2%) patients had mutated IgVH, and 20 (30.8%) had unmutated IgVH. The most frequently expressed VH gene family was found to be VH3 (47.7%) followed by VH4 (40%), VH1 (6.2%), VH2 (4.6%) and VH7 (1.5%), with no expression of VH5 or VH6 gene families. VH1-69 and VH3-21 which commonly overused in Western CLL were very low in our cohort. IgVH gene mutation status was significantly associated with the expression of CD38.
CONCLUSIONS: The frequency of IgVH gene families indicates significant difference in Chinese CLL patients compared with Western patients, suggesting involvement of ethnic and/or environmental factors in CLL disease initiation. The expression of them may be simple and reliable surrogates for the identification of IgVH mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18359082     DOI: 10.1016/j.leukres.2008.02.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  17 in total

1.  High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.

Authors:  Cheng Fang; Yun Zhuang; Li Wang; Lei Fan; Yu-Jie Wu; Run Zhang; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Wei Xu; Jian-Yong Li
Journal:  Cancer Sci       Date:  2013-06-07       Impact factor: 6.716

2.  Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.

Authors:  Min Xu; Lei Fan; Kou-Rong Miao; Peng Liu; Wei Xu; Jian-Yong Li
Journal:  Med Oncol       Date:  2011-09-01       Impact factor: 3.064

3.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

4.  Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia.

Authors:  Wen-Ting Wang; Hua-Yuan Zhu; Yu-Jie Wu; Yi Xia; Jia-Zhu Wu; Wei Wu; Jin-Hua Liang; Li Wang; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  J Cancer Res Clin Oncol       Date:  2018-01-03       Impact factor: 4.553

5.  Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation.

Authors:  Corey T Watson; Karyn M Steinberg; John Huddleston; Rene L Warren; Maika Malig; Jacqueline Schein; A Jeremy Willsey; Jeffrey B Joy; Jamie K Scott; Tina A Graves; Richard K Wilson; Robert A Holt; Evan E Eichler; Felix Breden
Journal:  Am J Hum Genet       Date:  2013-03-28       Impact factor: 11.025

6.  Association between polymorphism of CD20 gene and chronic lymphocytic leukemia in Chinese population.

Authors:  Cheng Fang; Dan-Xia Zhu; Li Wang; Lei Fan; Ji Xu; Jia-Zhu Wu; Ting-Xun Lu; Jian-Yong Li; Chang-Ping Wu; Wei Xu
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

Authors:  Wei Xu; Xin Cao; Kou-Rong Miao; Chun Qiao; Yu-Jie Wu; Qiong Liu; Lei Fan; Jian-Yong Li
Journal:  Int J Hematol       Date:  2009-07-24       Impact factor: 2.490

8.  Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.

Authors:  Yi Xia; Lei Fan; Li Wang; Robert Peter Gale; Man Wang; Tian Tian; Wei Wu; Liang Yu; Yao-Yu Chen; Wei Xu; Jian-Yong Li
Journal:  Oncotarget       Date:  2015-03-10

9.  Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia.

Authors:  I González-Gascón Y Marín; J A Hernández; A Martín; M Alcoceba; M E Sarasquete; A Rodríguez-Vicente; C Heras; N de Las Heras; R Fisac; A García de Coca; I de la Fuente; M Hernández-Sánchez; I Recio; J Galende; G Martín-Núñez; J M Alonso; J M Hernández-Rivas; M González
Journal:  Biomed Res Int       Date:  2014-03-30       Impact factor: 3.411

10.  Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.

Authors:  Zengjun Li; Fei Li; Shuhua Yi; Zhimin Gu; Zhen Yu; Yan Xu; Xiaoyan Feng; Wei Liu; Dehui Zou; Junyuan Qi; Fenghuang Zhan; Lugui Qiu
Journal:  BMC Cancer       Date:  2015-07-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.